Guidelines for treatment of candidiasis.

By P. Pappas, J. Rex, J. Sobel, S. Filler, W. Dismukes, T. Walsh, J. Edwards. Clinical Infectious Diseases, 2004

1,413 citations recorded by the source corpus.

Subfields: Infectious Diseases, Oncology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/0763f09361b8f9df9bd21f5385f453e6bf98a901

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. M. Nucci
4. J. Fishman
5. E. Anaissie
6. J. Guinea

In Oncology

1. J. Fishman

Citations in the corpus

• Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America (2010, neutral): “Members of the Expert Panel were provided a conflict of interest disclosure statement from the IDSA and were asked to identify ties to companies developing products that might be affected by promulgation of the guideline.”
• Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. (2007, background): “fungin, and voriconazole [12–14], and most have been”
• Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus (2004, background): “Trick et al. (101) have demonstrated that among the Candida spp. C. glabrata alone has increased in incidence as a cause of BSIs in U.S. intensive care units since 1993.”
• Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 (2007, background): “, fluconazole, amphotericin B, or echinocandin) will be tailored to the local pattern of the most prevalent Candida species and any prior administration of azoles drugs (44).”
• Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009, background): “The differences observed in the use of antifungal agents based on the different Candida species may, in part, be explained by the variations in their susceptibility profiles (when available), empirical therapy based on existing treatment guidelines [10], or differences in clinical practice, includin”
• The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. (2005, background): “comial bloodstream infection in the United States [1, 2]. Candidemia is frequently associated with the signs and symptoms of sepsis syndrome [3, 4 ]. A recent study of the epidemiology of sepsis revealed that the annual number of cases of sepsis caused by fungal organisms increased by 207% between ”
• GENETIC CONTROL OF CANDIDA ALBICANS BIOFILM DEVELOPMENT (2010, neutral): “Although these organisms are usually benign, they can cause infection if immune function in the host is impaired or if an environmental niche becomes availabl”
• Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 (2005, background): “TPN 125 (40) 57 (38) 7 (27) 7 (23) 3 (25) 43 (57) Catheter related 108 (31) 53 (31) 3 (10) 7 (22) 2 (17) 42 (54) Prior antibiotic therapy 298 (88) 156 (91) 21 (72) 26 (84) 10 (91) 70 (91) Prior antifungal therapy 57 (17) 12 (7) 7 (21) 4 (13) 9 (75) 20 (26) Death by day 3–7 74 (22) 42 (24) 9 (31) 11 ”